

Substitute Form (Modified) PTO-1449	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 10276-067001	Application No. 10/038,686
Information Disclosure Statement by Applicant (Use several sheets if necessary)		Applicant Tihamer Orban	
		Filing Date January 4, 2002	Group Art Unit 1646

U.S. Patent Documents

Examiner Initial	Desig. ID	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date If Appropriate
<i>JS</i>	AA	6,110,746	August 29, 2000	Cohen et al.	436	506	
	AB						
	AC						

Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	AD							
	AE							
	AF							

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
<i>JS</i>	AG	Aanstoot et al., "Identification and Characterization of Glima 38, a Glycosylated Islet Cell", J. Clin Invest., Jun 15, 1996, 97(12):2772-2783.
	AH	Alcalde et al., "Cloning of Candidate Autoantigen Carboxypeptides H", J. Autoimmun, 1996, 9(4):525-8
	AI	Argentaro, A., Concannon, P. and Harley, V.R. (2001) Linkage analysis of SOX13, the ICA12 autoantigen gene, in families with type 1 diabetes. Molecular Genetics and Metabolism 72, 356-359.
	AJ	Boitard et al., "Peripherin: An islet antigen that is cross-reactive with nonobese", (1992) Proc Natl Acad Sci USA, 89(1):172-6
	AK	Castano et al., "Identification and Cloning of a Granule Autoantigen", J Clin Endocrinol Metab, (1991);73(6):1197-201
	AL	Dionisi et al., "Target antigens in autoimmune diabetes: pancreatic gangliosides", Ann 1st Super Sanita, (1997);33(3):433-5
	AM	Dotta et al., "Autoimmunity to the GM2-1 Islet Ganglioside Before", Diabetes, (1996);45(9):1193-6
	AN	Elias et al., "Peptide therapy for diabetes in NOD mice", Lancet, (1994);343(8899):704-6
<i>JS</i>	AO	Elias et al., "Induction of diabetes in standard mice by", Eur J Immunol., (1995);25(10):2851-7.

Examiner Signature <i>JS</i> 1/25/05	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 10276-067001	Application No. 10/038,686
Information Disclosure Statement by Applicant (Use several sheets if necessary)		Applicant Tihamer Orban	
		Filing Date January 4, 2002	Group Art Unit 1646

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
<i>[Signature]</i>	AP	Karlsen et al., "Cloning and primary structure of a human islet isoform of", Proc Natl Acad Sci USA, (1991);88(19):8337-41
<i>[Signature]</i>	AQ	Kasimiotis et al., "Sex-Determining Region Y-Related Protein SOX13", (2000), Diabetes, 49(4):555-61.
<i>[Signature]</i>	AR	Kukreja et al., "Autoimmunity and Diabetes", (1999), J. Clinical Endocrin. & Metab., 84(12):4371-4378
<i>[Signature]</i>	AS	Leslie et al., "Autoantigens IA-2 and GAD in type I (insulin-dependent) diabetes", Diabetologia 42:3-14, 1999
<i>[Signature]</i>	AT	Pietropaolo et al., "Islet Cell Autoantigen 69 kD (ICA69)", J Clin Invest 1993; 92:359-371
<i>[Signature]</i>	AU	Rabin et al., "Islet Cell Antigen 512 Is a Diabetes-Specific", (1994) J. Immunol., 152 (6), 3183-3188
<i>[Signature]</i>	AV	Ramiya et al., "Immunization Therapies in the Prevention of Diabetes", (1997), J. Autoimmunity, 10:287-292
<i>[Signature]</i>	AW	Ramiya et al., "Antigen Based Therapies to Prevent Diabetes in NOD Mice", (1996), 9:349-356
<i>[Signature]</i>	AX	Simone et al., "Immunologic "Vaccination" for the Prevention", (1999), Diabetes Care, 22:B7-B15
<i>[Signature]</i>	AY	Xie et al., "Autoantibodies to IA-2 and IA-2 β in Insulin-Dependent", (1997) J Immunol 159:3662-3667
<i>[Signature]</i>	AZ	Zhang et al., "Autoantibodies to IA-2 in IDDM", (1997) Diabetes 46:40-43;

Examiner Signature <i>[Signature]</i> 1/25/02	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

OCT 15 2002

Sheet 1 of 1

Substitute Form PTO-1449 (Modified) Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 10276-067001	Application No. 10/038,686
	Applicant Tihamer Orban		
	Filing Date January 4, 2002	Group Art Unit 1646	

U.S. Patent Documents

Examiner Initial	Desig. ID	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date If Appropriate
<i>FS</i>	AA	5,891,435	April 6, 1999	Muir et al.			
	AB						
	AC						
	AD						
	AE						
	AF						

RECEIVED

OCT 17 2002

TECH CENTER 1600/2900

Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	AG							
	AH							
	AI							
	AJ							
	AK							

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
	AL	
	AM	
	AN	
	AO	

Examiner Signature <i>FS</i> 1/25/05	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	